AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27781421 — intervention group
Group type: COMPARATOR
Intervention: Fosdagrocorat 5, 10, or 30 mg (single doses)
Number of subjects: 30
Study 27781421 — intervention group
Group type: COMPARATOR
Intervention: Fosdagrocorat 20 mg QD (multiple doses for 12 days)
Number of subjects: 30
Study 27781421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single and multiple doses)
Number of subjects: 30
Study 16172794 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 60 mg/day
Number of subjects: 0
Study 16172794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12608739 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to eat more fatty fish
Number of subjects: 452
Study 12608739 — intervention group
Group type: COMPARATOR
Intervention: No fish advice (Control)
Number of subjects: 452
Study 10587476 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-salbutamol 1.25 mg
Number of subjects: 0
Study 10587476 — intervention group
Group type: COMPARATOR
Intervention: (RS)-salbutamol 2.5 mg
Number of subjects: 0
Study 10587476 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-salbutamol
Number of subjects: 0
Study 10587476 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-salbutamol and (RS)-salbutamol
Number of subjects: 0
Study 8735733 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching of the cervix and stripping of the membranes
Number of subjects: 293
Study 8735733 — intervention group
Group type: COMPARATOR
Intervention: Non-stretching/stripping (control group)
Number of subjects: 293
Study 8735733 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching of the cervix and stripping of the membranes (for patients at 41 weeks' gestation or more)
Number of subjects: 293
Study 8735733 — intervention group
Group type: COMPARATOR
Intervention: Non-stretching/stripping (control group for patients at 41 weeks' gestation or more)
Number of subjects: 293
Study 1751787 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G (400 mg/kg body wt)
Number of subjects: 40
Study 1751787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline; 8 mL/kg body wt)
Number of subjects: 40
Study 1751787 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G
Number of subjects: 40
Study 7076630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate withdrawal
Number of subjects: 27
Study 7076630 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate (continued treatment)
Number of subjects: 27
Study 31030872 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavior Program (a brief, home‐based adaptation of the child‐directed interaction phase of parent‐child interaction therapy)
Number of subjects: 60
Study 31030872 — intervention group
Group type: COMPARATOR
Intervention: Standard pediatric primary care
Number of subjects: 60
Study 28273891 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (350 mg daily for 24 weeks)
Number of subjects: 52
Study 28273891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26354287 — intervention group
Group type: EXPERIMENTAL
Intervention: Admitting service (AS) assessment of VTE risk
Number of subjects: 100
Study 26354287 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis ordered based on AS assessment
Number of subjects: 100
Study 23955487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement at forehead
Number of subjects: 256
Study 23955487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement at abdomen
Number of subjects: 256
Study 23955487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement at sternum
Number of subjects: 256
Study 23955487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement
Number of subjects: 256
Study 22348388 — intervention group
Group type: EXPERIMENTAL
Intervention: AFXL-PDT
Number of subjects: 15
Study 22348388 — intervention group
Group type: COMPARATOR
Intervention: PDT
Number of subjects: 15
Study 19056853 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill practice (moving treadmill)
Number of subjects: 24
Study 19056853 — intervention group
Group type: COMPARATOR
Intervention: Nonmoving treadmill (control)
Number of subjects: 24
Study 18073337 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention program promoting healthy eating and physical activity
Number of subjects: 18
Study 18073337 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline survey
Number of subjects: 18
Study 16926933 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm PDA with angina diagnosis software
Number of subjects: 18
Study 16926933 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 18
Study 12027338 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting group (n = 50)
Number of subjects: 100
Study 12027338 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 100
Study 10491058 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of strontium salts
Number of subjects: 0
Study 10491058 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 7742579 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA only
Number of subjects: 43
Study 7742579 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + MP
Number of subjects: 43
Study 7742579 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + MP + Aza
Number of subjects: 43
Study 7742579 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-2R levels increase
Number of subjects: 43
Study 7742579 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-2R levels
Number of subjects: 43
Study 2073001 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg b.i.d.)
Number of subjects: 21
Study 2073001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7466512 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellenbosch valve
Number of subjects: 0
Study 7466512 — intervention group
Group type: EXPERIMENTAL
Intervention: Other anaesthetic scavenging devices
Number of subjects: 0
Study 7466512 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 31287117 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice (2 cups daily for 12 weeks)
Number of subjects: 37
Study 28400341 — intervention group
Group type: EXPERIMENTAL
Intervention: TGP plus acitretin
Number of subjects: 108
Study 28400341 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus acitretin
Number of subjects: 108
Study 25701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 34
Study 25701801 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list Control (WLC)
Number of subjects: 34
Study 24131320 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation
Number of subjects: 36282
Study 24131320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 21389144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplementation (Creon Forte, 100,000 IU lipase)
Number of subjects: 11
Study 21389144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19924586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 19
Study 19924586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17901383 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS+TRT
Number of subjects: 88
Study 17901383 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 88
Study 17901383 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS+TRT
Number of subjects: 88
Study 17901383 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 88
Study 15779677 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10686535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (exact dosage and duration not available)
Number of subjects: 0
Study 10686535 — intervention group
Group type: COMPARATOR
Intervention: Interferons (exact dosage and duration not available)
Number of subjects: 0
Study 9296731 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin use (including folic acid, vitamin B12, vitamin B6, vitamin C, and zinc)
Number of subjects: 0
Study 9296731 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin consumption including 0.8 mg folic acid
Number of subjects: 0
Study 9296731 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-rich diet, vitamin supplementation, food fortification with vitamins
Number of subjects: 0
Study 1592976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice formulations containing NaF, xylitol, or NaF/xylitol
Number of subjects: 0
Study 1592976 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 6731772 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.07 mg/kg
Number of subjects: 0
Study 6731772 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.12 mg/kg
Number of subjects: 0
Study 6731772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 30275698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg daily
Number of subjects: 2698
Study 30275698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg daily
Number of subjects: 2698
Study 30275698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2698
Study 30275698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2698
Study 30275698 — intervention group
Group type: COMPARATOR
Intervention: Active-control
Number of subjects: 2698
Study 27434476 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous microsliced modified cartilage perichondrium shield graft
Number of subjects: 51
Study 27434476 — intervention group
Group type: COMPARATOR
Intervention: Autologous temporalis muscle fascia graft
Number of subjects: 51
Study 24643639 — intervention group
Group type: EXPERIMENTAL
Intervention: JET combination therapy
Number of subjects: 288
Study 22207105 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin
Number of subjects: 0
Study 22207105 — intervention group
Group type: COMPARATOR
Intervention: Group I (normal epithelia)
Number of subjects: 0
Study 22207105 — intervention group
Group type: COMPARATOR
Intervention: Group II (degenerated epithelia)
Number of subjects: 0
Study 22207105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithogenic diet group
Number of subjects: 0
Study 22207105 — intervention group
Group type: COMPARATOR
Intervention: Normal diet group
Number of subjects: 0
Study 20518938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-reinforced posts (FRPs) pretreated
Number of subjects: 144
Study 20518938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-reinforced posts (FRPs) untreated
Number of subjects: 144
Study 20518938 — intervention group
Group type: EXPERIMENTAL
Intervention: Long threaded metal posts (TMPs)
Number of subjects: 144
Study 20518938 — intervention group
Group type: EXPERIMENTAL
Intervention: Long (10 mm) pretreated FRP
Number of subjects: 144
Study 20518938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation with adhesive resin cement
Number of subjects: 144
Study 20518938 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact natural crowns)
Number of subjects: 144
Study 18461010 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Resistance Training (SRT)
Number of subjects: 549
Study 18461010 — intervention group
Group type: EXPERIMENTAL
Intervention: All-round Physical Exercise (APE)
Number of subjects: 549
Study 18461010 — intervention group
Group type: COMPARATOR
Intervention: Reference Intervention (REF)
Number of subjects: 549
Study 15702515 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan nasal spray (5 mg)
Number of subjects: 0
Study 15702515 — intervention group
Group type: COMPARATOR
Intervention: Oral rizatriptan tablet (5 mg)
Number of subjects: 0
Study 12848628 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg/day for 3 weeks)
Number of subjects: 29
Study 12848628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12848628 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 29
Study 12848628 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone and Placebo
Number of subjects: 29
Study 10700887 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy for locally unresectable cancer in the oral cavity, pharynx, and nose and paranasal sinus
Number of subjects: 0
Study 10700887 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus adjuvant chemotherapy for advanced N stage nasopharyngeal cancer
Number of subjects: 0
Study 10700887 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy for advanced T stage nasopharyngeal cancer
Number of subjects: 0
Study 10700887 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant and/or concurrent chemoradiotherapy for T2 and T3 laryngeal and hypopharyngeal cancer
Number of subjects: 0
Study 10700887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimens including cisplatin plus 5-fluorouracil
Number of subjects: 0
Study 10700887 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 10700887 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ function preservation studies
Number of subjects: 0
Study 9038610 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-2 (rIL-2) with chemotherapy (5-fluorouracil and leucovorin)
Number of subjects: 17
Study 9038610 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy alone
Number of subjects: 17
Study 1665285 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (A-64077) 600 mg q.i.d. for 14 days
Number of subjects: 0
Study 1665285 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of LTB4 levels using RP-HPLC or RIA
Number of subjects: 0
Study 370894 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque (metrizamide)
Number of subjects: 37
Study 370894 — intervention group
Group type: COMPARATOR
Intervention: Isopaque Cerebral
Number of subjects: 37
Study 31144205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Short Warwick‐Edinburgh Mental Well‐being Scale (SWEMWBS)
Number of subjects: 1331
Study 28511023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification plus DHA-CHO-VE (docosahexaenoic acid, choline, and vitamin E)
Number of subjects: 40
Study 28511023 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification plus placebo
Number of subjects: 40
Study 25529395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia severity index (PSI)
Number of subjects: 100
Study 25529395 — intervention group
Group type: EXPERIMENTAL
Intervention: CURB-65 score
Number of subjects: 100
Study 25529395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-adrenomedullin and pro-atrial natriuretic peptide blood biomarkers
Number of subjects: 100
Study 25529395 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 100
Study 23072637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity 40 km cycling (morning)
Number of subjects: 12
Study 23072637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity 40 km cycling (evening)
Number of subjects: 12
Study 23072637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity 40 km cycling (morning and evening)
Number of subjects: 12
Study 23072637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity 40 km cycling
Number of subjects: 12
Study 20957430 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 683
Study 20957430 — intervention group
Group type: COMPARATOR
Intervention: Cytosol assays
Number of subjects: 683
Study 20957430 — intervention group
Group type: COMPARATOR
Intervention: Immunohistochemistry (IHC)
Number of subjects: 683
Study 19791640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery Motivational Climate (MMC)
Number of subjects: 117
Study 19791640 — intervention group
Group type: COMPARATOR
Intervention: Low-Autonomy (LA)
Number of subjects: 117
Study 19791640 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 117
Study 18035076 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2617
Study 18035076 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2617
Study 18035076 — intervention group
Group type: EXPERIMENTAL
Intervention: Early smaller studies
Number of subjects: 2617
Study 18035076 — intervention group
Group type: COMPARATOR
Intervention: Occluded Artery Trial and Total Occlusion Study of Canada 2
Number of subjects: 2617
Study 16649820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 539
Study 16649820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 539
Study 16649820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (pooled doses)
Number of subjects: 539
Study 16649820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 539
Study 16649820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 12414914 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 0
Study 12414914 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 0
Study 12414914 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 0
Study 12414914 — intervention group
Group type: EXPERIMENTAL
Intervention: weight-adjusted heparin
Number of subjects: 0
Study 12414914 — intervention group
Group type: EXPERIMENTAL
Intervention: oral compounds
Number of subjects: 0
Study 10400458 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant infusion containing tocopherol and ascorbate
Number of subjects: 50
Study 10400458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant infusion)
Number of subjects: 50
Study 8524969 — intervention group
Group type: EXPERIMENTAL
Intervention: brotizolam 0.25 mg
Number of subjects: 6
Study 8524969 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam 0.25 mg
Number of subjects: 6
Study 8524969 — intervention group
Group type: COMPARATOR
Intervention: placebo without noise
Number of subjects: 6
Study 8524969 — intervention group
Group type: COMPARATOR
Intervention: placebo with noise
Number of subjects: 6
Study 2338695 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training Protocol (ITP) - 15 subjects
Number of subjects: 42
Study 2338695 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Training Protocol (CTP) - 15 subjects
Number of subjects: 42
Study 2338695 — intervention group
Group type: COMPARATOR
Intervention: Control - 12 subjects
Number of subjects: 42
Study 111286 — intervention group
Group type: EXPERIMENTAL
Intervention: task + reward
Number of subjects: 12
Study 111286 — intervention group
Group type: EXPERIMENTAL
Intervention: task + alcohol
Number of subjects: 12
Study 111286 — intervention group
Group type: EXPERIMENTAL
Intervention: task + reward + alcohol
Number of subjects: 12
Study 111286 — intervention group
Group type: COMPARATOR
Intervention: task only
Number of subjects: 12
Study 29273936 — intervention group
Group type: EXPERIMENTAL
Intervention: 11+ Kids warm-up programme
Number of subjects: 3895
Study 29273936 — intervention group
Group type: COMPARATOR
Intervention: Usual warm-up
Number of subjects: 3895
Study 27108817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (midazolam, fentanyl, and propofol)
Number of subjects: 140
Study 27108817 — intervention group
Group type: COMPARATOR
Intervention: Group II (fentanyl and propofol)
Number of subjects: 140
Study 23982942 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey administration (n = 99)
Number of subjects: 295
Study 23982942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail with followup telephone call (n = 98)
Number of subjects: 295
Study 23982942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail with followup letter (n = 98)
Number of subjects: 295
Study 23982942 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey preference (n = 166)
Number of subjects: 295
Study 23072847 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoyo Bitters (1206.5 mg/kg)
Number of subjects: 20
Study 23072847 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoyo Bitters (804.3 mg/kg)
Number of subjects: 20
Study 23072847 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoyo Bitters (various dosages)
Number of subjects: 20
Study 20397459 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-moxibustion
Number of subjects: 47
Study 20397459 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 47
Study 20397459 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-acupuncture
Number of subjects: 47
Study 20397459 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study 18787516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (N = 40)
Number of subjects: 80
Study 18787516 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium diet (N = 40)
Number of subjects: 80
Study 16106331 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational audiotapes on self‐care behaviors (SCBs) to manage side effects
Number of subjects: 71
Study 16106331 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study 12407324 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hormone replacement therapy (HRT)
Number of subjects: 6
Study 12407324 — intervention group
Group type: COMPARATOR
Intervention: Tibolone
Number of subjects: 6
Study 10369404 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 122
Study 10369404 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 122
Study 7785477 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program for methadone clients
Number of subjects: 0